IL1B and atherosclerosis: The CANTOS (NCT01327846) clinical trial provided critical evidence that targeting IL1β alone with the monoclonal antibody canakinumab can reduce major cardiovascular events along with proinflammatory cytokines (IL-6) and high sensitivity C reactive protein in patients with atherosclerosis.